Compare PGEN & HURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | HURN |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2013 | 2004 |
| Metric | PGEN | HURN |
|---|---|---|
| Price | $7.13 | $162.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $8.33 | ★ $204.40 |
| AVG Volume (30 Days) | ★ 6.0M | 329.8K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.03 | ★ 1.34 |
| Revenue | $230,981,000.00 | ★ $1,699,143,000.00 |
| Revenue This Year | $1,115.92 | $11.80 |
| Revenue Next Year | $81.04 | $8.23 |
| P/E Ratio | $248.00 | ★ $121.23 |
| Revenue Growth | N/A | ★ 11.65 |
| 52 Week Low | $2.99 | $84.88 |
| 52 Week High | $7.49 | $186.78 |
| Indicator | PGEN | HURN |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 68.26 |
| Support Level | $3.96 | $158.12 |
| Resistance Level | $7.32 | $172.67 |
| Average True Range (ATR) | 0.44 | 5.78 |
| MACD | 0.02 | -0.26 |
| Stochastic Oscillator | 75.70 | 88.64 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.